340B Vigilance

Pharma manufacturers face the problem of paying unauthorized rebates to third-party payers for prescriptions bought at a 340B discount.

Companies are increasingly challenged with automating and paying multi-tier channels and indirect partners

• No simple linkage between sales and dispensing transactions means companies cannot easily determine if stock was acquired at 340B prices.
• As part of rebate contracts, payers submit transactions that were dispensed by pharmacies using product acquired at 340B prices.
• With heavy discounting and penny pricing, manufacturers may pay more in discounts than the drug’s original price, albeit to multiple entities.